632 related articles for article (PubMed ID: 24643967)
1. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
2. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.
Chhabra P; Chen X; Weiss SR
Drug Saf; 2013 Nov; 36(11):1117-23. PubMed ID: 24078293
[TBL] [Abstract][Full Text] [Related]
3. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
[TBL] [Abstract][Full Text] [Related]
4. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
5. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
[TBL] [Abstract][Full Text] [Related]
6. Comparing drug safety of hepatitis C therapies using post-market data.
Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
[TBL] [Abstract][Full Text] [Related]
7. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
8. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
9. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
12. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
13. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
Iyer G; Marimuthu SP; Segal JB; Singh S
Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
[TBL] [Abstract][Full Text] [Related]
14. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
15. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell NR; Wilson JP
Pharmacotherapy; 2004 Jun; 24(6):743-9. PubMed ID: 15222664
[TBL] [Abstract][Full Text] [Related]
16. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
[TBL] [Abstract][Full Text] [Related]
17. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
[TBL] [Abstract][Full Text] [Related]
18. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
19. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs.
Arora A; Jalali RK; Vohora D
Ther Clin Risk Manag; 2017; 13():1195-1203. PubMed ID: 28979130
[TBL] [Abstract][Full Text] [Related]
20. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection.
Xu R; Wang Q
BMC Bioinformatics; 2014 Jan; 15():17. PubMed ID: 24428898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
